# Best Practices for Communication Between IND Sponsors and FDA During Drug Development - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/good-review-practices/best-practices-for-communication-between-ind-sponsors-and-fda-during-drug-development/2c093434-6b20-4df3-af2a-d7af81ab3fd8

> FDA guidance document: Best Practices for Communication Between IND Sponsors and FDA During Drug Development. Issue date: December 29, 2017. Get complete insights and analysis.

---

## Details

- Title: Best Practices for Communication Between IND Sponsors and FDA During Drug Development
- Communication Type: Good Review Practices
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2017-12-29
- Last Changed: 2020-04-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-6564">FDA-2017-D-6564</a>

## Related Documents

- [Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs](https://www.globalkeysolutions.net/guidances/guidance-document/atopic-dermatitis-timing-of-pediatric-studies-during-development-of-systemic-drugs/287c413c-cc5e-49ee-af83-9d7183bc4f4d)
- [Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/formal-meetings-between-the-fda-and-sponsors-or-applicants-of-bsufa-products-guidance-for-industry/8a1d80ed-d462-41f3-b1cd-7df78736a49b)
- [Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling Good Review Practice](https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-information-incorporated-into-human-prescription-drug-and-biological-products-labeling-good-review-practice/b745efcc-5e41-4458-a1d9-6827d55dd3a7)